Most major stock indexes across the globe ended the week higher, as renewed optimism around US-China trade talks lifted ...

Paris: Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare ...

Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

Sanofi paid $55 million to partner with the biotech in 2019 and handed over a further $22 million to expand the collaboration ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...